Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)

May 4, 2023 11:27 AM EDTUpdated 01:11 PM

Novo Nordisk to restrict starter dose supply for weight loss drug Wegovy

Nicole DeFeudis

Editor

Faced with “all-time high levels” of new patients starting Novo Nordisk’s GLP-1 products, the company is temporarily restricting its supply of lower Wegovy dose strengths …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk to restrict starter dose supply for weight loss drug Wegovy

Nicole DeFeudis

Editor

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No­vo Nordisk to re­strict starter dose sup­ply for weight loss drug We­govy

Nicole DeFeudis

Editor

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Novo Nordisk to restrict starter dose supply for weight loss drug Wegovy

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence